top of page


Updated: Feb 11, 2022

In this issue of GOLD, we take a dive into the pharmaceutical industry’s key news stories from the past few months, covering the latest mergers and acquisitions, approvals, and clinical trial results.

03 September

BMS obtains exclusive global license for Evotec’s neurodegenerative drug

06 September

AstraZeneca and Amgen’s Tezepelumab shows positive phase III results for severe asthma

07 September

ILC Therapeutics announces completion of £3.5m pre-IPO funding round

08 September

Sanofi seeks to acquire Kadmon to expand its transplant portfolio

10 September

MHRA approves marketing authorisation for Pfizer’s JAK1 inhibitor Cibinqo

14 September

Beckley Psytech announces ‘world-first’ trial of psilocybin for headaches

20 September

AstraZeneca and Daiichi Sankyo’s Enhertu decreases progression or death from breast cancer by 72%

21 September

FDA approves Exlixis’ Cabometyx for the treatment of thyroid cancer

04 October

MSD’s molnupiravir halves hospitalisation and death in COVID-19 patients

08 October

NUC-7738 drug derived from fungus found to be beneficial in treating cancer

13 October

Sanofi’s BTK inhibitor tolebrutinib shows promising long-term data as MS treatment

20 October

FSD and Covar to explore psychoactive compound LUCID-Psych as treatment for major depressive disorders

Read next

Subscribe to GOLD


Sign up to receive a weekly roundup of our latest articles, interviews and more 

bottom of page